Excellent Hemodynamic Performance After Aortic Valve Neocuspidization Using Autologous Pericardium

BackgroundAortic valve neocuspidization (AVNeo) for trileaflet aortic reconstruction using autologous pericardium (Ozaki procedure) offers an alternative treatment modality to overcome drawbacks of conventional prosthetic replacement.MethodsBetween October 2016 and April 2019, 103 patients underwent surgery. Mean follow-up was 426 ± 270 days. Aortic stenosis the leading diagnosis in 80 (77.7%) regurgitation 23 (22.3%), respectively. age 54.0 16.4 years (range, 13.8-78.5). A bicuspid found 81 (78.6%). Transthoracic echocardiography performed at discharge 6 12 months after During AVNeo surgery sizing Abbott/St Jude Trifecta bioprosthesis (virtually implanted bioprosthesis; St Medical, Paul, MN) compare pressure gradients effective orifice area with published data.ResultsTrileaflet achieved all patients. In 38 neocommissures were created (36.9%). cross-clamp time 135 20 minutes. Four reoperation; overall freedom from reoperation 96.1%. Echocardiographic 6- 12-months available 93.8% did not show any change hemodynamic parameters compared discharge. Comparison between virtually Bioprosthesis revealed a significantly lower mean gradient (8.5 3.7 mm Hg vs 10.2 2.0 Hg, P < .001) higher (2.2 0.7 cm2 2.1 0.4 cm2, = .037) AVNeo.ConclusionsAVNeo shows low rates within first 2 years. The performance is excellent, remain stable year. replacement. Between data. Trileaflet AVNeo.